Slingerlands, NY, United States of America

Lawrence S Zisman

This inventor holds 9 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Pulmokine, Inc., Gilead Sciences, Inc., Rensselaer Center for Translational Research, Inc.. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lawrence S Zisman. Retrieved from https://idiyas.com/inventor/lawrence-s-zisman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 77.8

 

 

Average Co-Inventor Count = 1.1

ph-index = 3

Forward Citations = 25(Granted Patents)


Location History:

  • Rensselaer, NY (US) (2018)
  • San Diego, CA (US) (2020)
  • Slingerlands, NY (US) (2013 - 2024)

Company Filing History:


Years Active: 2013-2024

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Lawrence S Zisman

Introduction

Lawrence S Zisman is a notable inventor based in Slingerlands, NY (US), recognized for his significant contributions to the field of pulmonary health. With a total of nine patents to his name, Zisman has developed innovative methods and treatments that address critical health issues.

Latest Patents

Zisman’s latest patents include groundbreaking methods for detecting and treating pulmonary hypertension. One of his inventions describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. This method can be utilized to quantify changes in phosphopeptide amounts through parallel reaction monitoring mass spectrometry techniques. The invention serves to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. Additionally, it can identify subjects who may require more aggressive therapeutic interventions or alternative treatments. Another significant patent focuses on combination therapy for treating pulmonary hypertension. This method involves using a combination of a PDGF receptor kinase inhibitor, PDE5 inhibitor, and an endothelin receptor antagonist to treat pulmonary disorders, such as pulmonary arterial hypertension. The compounds in this patent can inhibit cell growth and proliferation, targeting the underlying pathology of PAH.

Career Highlights

Throughout his career, Zisman has worked with prominent companies in the pharmaceutical and biotechnology sectors, including Pulmokine, Inc. and Gilead Sciences, Inc. His work has had a profound impact on the development of therapies aimed at improving patient outcomes in pulmonary health.

Collaborations

Zisman has collaborated with notable professionals in his field, including Timothy S Wiedmann and Amir A Naqwi. These collaborations have contributed to the advancement of research and innovation in pulmonary treatments.

Conclusion

Lawrence S Zisman’s contributions to the field of pulmonary health through his patents and collaborations highlight his role as a leading inventor. His innovative approaches to detecting and treating pulmonary hypertension demonstrate the potential for significant advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…